Stockreport

Mesoblast reports Q2 revenue surge of 66% on strong Ryoncil sales [Seeking Alpha]

Mesoblast Limited - American Depositary Shares  (MESO) 
US:NASDAQ Investor Relations: investorsmedia.mesoblast.com
PDF Growth driven by strong sales of Ryoncil (remestemcel-L-rknd). Ryoncil is the first FDA-approved mesenchymal stromal cell therapy. It remains the only approved treatm [Read more]